Envestnet Asset Management Inc. Sells 319,779 Shares of Genmab A/S (NASDAQ:GMAB)

Envestnet Asset Management Inc. reduced its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 30.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 723,781 shares of the company's stock after selling 319,779 shares during the quarter. Envestnet Asset Management Inc. owned 0.11% of Genmab A/S worth $15,105,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock valued at $636,000 after buying an additional 12,654 shares during the period. AIMZ Investment Advisors LLC acquired a new stake in shares of Genmab A/S during the fourth quarter worth approximately $3,525,000. HighTower Advisors LLC purchased a new position in Genmab A/S during the third quarter valued at approximately $273,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Genmab A/S by 229.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after buying an additional 34,652 shares during the period. Finally, Blue Trust Inc. lifted its position in Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after buying an additional 1,442 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GMAB. Truist Financial lowered their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Finally, Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded up $0.49 during midday trading on Friday, hitting $20.04. The company's stock had a trading volume of 1,135,288 shares, compared to its average volume of 1,038,357. The stock's 50 day simple moving average is $20.54 and its 200 day simple moving average is $21.14. The stock has a market capitalization of $13.26 billion, a price-to-earnings ratio of 11.52, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.